@FierceBiotech: Can Sanofi's partnership with Regeneron redeem the French biotech's R&D reputation? Read | Follow @FierceBiotech
@JohnCFierce: J&J team marks another setback on depression as mid-stage study flops. Story | Follow @JohnCFierce
@DamianFierce: Merck takes aim at Sanofi with a Lantus biosimilar of its own. More | Follow @DamianFierce
@EmilyMFierce: Gates Foundation delivers an $11.8M grant to fuel tuberculosis R&D. News | Follow @EmilyMFierce
> After last week's 8 successful biotech IPOs, another 6 life sciences companies are expected to go public this week. More
> Federal prosecutors in New York are looking into Teva's ($TEVA) marketing practices for Copaxone and Azilect, investigating possible violations of the False Claims Act, according to Bloomberg. Article
> Sarepta ($SRPT) is touting positive safety results for AVI-7288, a Phase I treatment for the bioterror agent Marburg virus infection. News
@FierceMedDev: Hackers broke into the Big 3--and left the door open for months, report says. Story | Follow @FierceMedDev
@MarkHFierce: Yes, med tech industry, you should watch India's regulatory reform process, but regulators aren't exactly rushing. Item | Follow @MarkHFierce
@MichaelGFierce: ICYMI: Check out our special report: The top drug delivery partnerships of 2013. Report from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Researchers at Harvard and MIT develop innovative hearing aid chip. More | Follow @EmilyWFierce
> WSJ: Device VC funding drops to 8-year lows, but seeds are in place for a rebound. Story
> Roche + Cancer Genetics will expand cancer molecular Dx testing into warmer waters. Article
> Medtronic faces another pretrial setback over its Infuse bone growth implant. News
Pharma News
@FiercePharma: Feds put Teva's Copaxone, Azilect marketing under FCA microscope. Story | Follow @FiercePharma
@TracyStaton: Best-read story this AM in FiercePharma: FDA panel could give Bayer painkiller an edge over Pfizer. More | Follow @TracyStaton
@EricPFierce: The engagement is off for CFR and Adcock Ingram. Is a spurned suitor in the wings? News | Follow @EricPFierce
@GalenMoore: Painkillers: A heart-risk warning in place since Vioxx could get lifted--for just one drug. Story | Follow @GalenMoore
> FDA panel could give Bayer painkiller an edge over rivals from Pfizer, J&J. Piece
> Government call for more HPV vaccination could boost GSK and Merck. Story
> Should Teva take a break-up cue from Big Pharma? Goldman analyst says yes. More
> FDA Commissioner's India visit coincides with trade actions. News
> Feds put Teva's Copaxone, Azilect marketing under FCA microscope. Item
CRO News
> Covance's sales soar on a jump in late-stage testing. News
> AstraZeneca spares its WuXi-partnered drug in an R&D slash and burn. Story
> BioOutsource doubles its capacity in a bet on the biosimilars boom. Article
> Wellcome bets $4M on CRO Selcia's university team-up. News
> BioClinica plots an EU expansion in the midst of its latest merger. Article
> Report: CRO biz set for another boom. Item
Biotech IT News
> > Report: Boston Scientific, Medtronic and St. Jude's networks hacked last year. Story
> Big Pharma players team with NIH to build a diabetes genomics database. Article
> The FDA is making adverse event and recall data available to app developers. Story
> U.K.'s medical research council commits $52M to medical record bioinformatics. News
> The FDA will break up its electronic submission guidance into a series of documents. Article
> Oracle is bringing Siri-like speech recognition to clinical trials. Item